Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Braebon Medical Corporation | UNKNOWN |
| National Research Council, Canada | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
The BRAEBON VTS is a low-cost, portable device that is being developed to take continuous and real-time vital sign measurements of COVID-19 patients, both in the hospital and home setting. This study is being undertaken to test the BRAEBON VTS and validate against industry standards.
In response to the COVID-19 pandemic, the BRAEBON Vital Signs Monitor (VTS) has been developed with funding from the National Research Council of Canada Industrial Research Assistance Program through the federal government's Innovative Solutions Canada (ISC) program. The VTS will measure peripheral capillary oxygen saturation (SpO2) and pulse via photoplethysmography (PPG), temperature, blood pressure (BP), heart and respiration rates, electrocardiogram (ECG), head position and movement over a continuous period. This monitor can be used remotely, and importantly will be low-cost so it can be accessed widely. Data from the VTS is transmitted wirelessly to a portable basestation which is a smartphone or tablet device via a customized application. This study will test the VTS both within the clinical environment and in the remote home environment to see how well it monitors patients effected by COVID-19 needing care, as well as satisfying an unmet need for remote monitoring across the healthcare system.
This study will compare the newly developed VTS with an industry gold standard of polysomnography (PSG) in the sleep laboratory, or in the home with the MediByte Jr (home sleep apnea test).
Approximately 150 patients will be recruited to the study across two different settings which includes a hospital setting and a remote setting, within the home environment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients of the Sleep Disorders Laboratory | Monitoring vital signs |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| BRAEBON VTS | Device | The BRAEBON VTS is a portable device that continuously monitors vital signs. Participants in the study will wear the BRAEBON VTS for 24 hours. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Oximetry - overnight comparison between the VTS and gold-standard PSG | Time spent with oxygen saturation >=90%, time spent with oxygen saturation <= 88%, number of desaturations of >3% | Up to 24 hours (Overnight - between lights-off and lights-on as for standard overnight sleep recordings). |
| Cardiac Rate (heart rate/pulse) | beats per minute | Up to 24 hours (Overnight - between lights-off and lights-on as for standard overnight sleep recordings). |
| Blood Pressure (BP) | mmHg | evening and morning, in a 24 hour period |
| Temperature (forehead) | degrees celcius | evening and morning, in a 24 hour period |
| Body position (PSG and MediByte Jr) and head position (VTS) | minutes spent supine, lateral and prone | Up to 24 hours (Overnight - between lights-off and lights-on as for standard overnight sleep recordings). |
| Respiratory rate | breaths per minute | Up to 24 hours (Overnight - between lights-off and lights-on as for standard overnight sleep recordings). |
| Identification of artifact | e.g. movement | Up to 24 hours (Overnight - between lights-off and lights-on as for standard overnight sleep recordings). |
| Measure | Description | Time Frame |
|---|---|---|
| Develop guidelines for the VTS | After assessing the usability of the VTS in the sleep laboratory and remote use in the home. | Within 6 months |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients of who under the care of the sleep disorders lab
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Helen Driver, Phd | Queen's University and Kingston Health Sciences Centre | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kingston Health Sciences Centre | Kingston | Ontario | K7L 2V7 | Canada |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
Not provided
Not provided
Not provided
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |